profit from every $100 of sales.
$0$100
CG Oncology
$74.40+6.06% today
+74.9% in 1 year
1-year low $37.371-year high $80.68
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What CG Oncology sold, what it kept, and what it did with the cash.
Sales went from $191,000 in 2022 to $4.04 million in 2025, with -$161 million of profit last year.
SalesProfit
CG Oncology vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| CG Oncology | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads CG Oncology's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 1 | 4 | |
| – | 0 | 1 | -1 | |
| -35 | -55 | -115 | -191 | |
| -35 | -55 | -115 | -189 | |
| -35 | -49 | -88 | -161 | |
| -11.71 | -15.65 | -1.41 | -2.08 | |
| – | 100.0% | 100.0% | -15.0% | |
| -18,453.4% | -27,180.9% | -10,067.3% | -4,722.1% | |
| -18,556.5% | -23,827.0% | -7,729.5% | -3,985.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 148 | 199 | 755 | 792 |
| Cash | 88 | 8 | 257 | 32 |
| Total debt | 16 | 0 | 0 | 7 |
| Total liabilities | 23 | 15 | 21 | 39 |
| 125 | 185 | 733 | 753 | |
| 4 | 4 | 62 | 77 | |
| -19.7% | -23.6% | -12.3% | -19.8% | |
| -28.3% | -26.3% | -12.0% | -21.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -30 | -46 | -79 | -132 | |
| 0 | – | 0 | 0 | |
| -30 | -46 | -79 | -132 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 2 | 11 | 27 |
Valuation
- –
- –
- –
- 7.3×
- 1,644.9×
- –
- –
- -2.0%
- -2.4%
- 0.0%
Profitability
- -15.0%
- -4,722.1%
- -3,985.0%
- -3,904.3%
- -20.3%
- -19.4%
- -23.3%
- -16.4%
- -19.5%
- 2,620.9%
Growth
- +176.6%
- –
- −67.8%
- –
- +174.4%
Financial health
- -0.1×
- 0.01
- 0.7%
- –
- 24.63
- 31.25
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 22%of 946
Top 3%of 867
Bottom 31%of 986
What analysts expect
- Average price target
- $79.86
- Range
- $70.00 – $93.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 8, 2026 | -0.71 | -0.58 | −22.4% |
| Feb 27, 2026 | -0.51 | -0.61 | +16.4% |
| Nov 14, 2025 | -0.57 | -0.56 | −2.0% |
| Aug 8, 2025 | -0.54 | -0.49 | −10.2% |
| May 13, 2025 | -0.45 | -0.39 | −15.4% |
| Mar 28, 2025 | -0.48 | -0.41 | −17.1% |
| Aug 8, 2024 | -0.28 | -0.42 | +33.3% |
| May 9, 2024 | -0.36 | -0.35 | −2.9% |
News
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineYahoo Finance · Oct 27, 2026Champions Oncology signals fiscal 2027 momentum as Q1 revenue reaches $15.2M and gross margin improves to 50%Seeking Alpha · Sep 10, 2026SA Asks: What are the most promising oncology companies right now?Seeking Alpha · Aug 22, 2026Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27MSeeking Alpha · Aug 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
40No pass
Philip Fisher
40No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
34No pass
Terry Smith
31No pass
Questions about CG Oncology
Is CG Oncology a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the CG Oncology AI analysis
What does CG Oncology do?
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. It is in Biotechnology, based in Dallas, TX, United States, with 142 employees.
Does CG Oncology pay a dividend?
No. CG Oncology does not pay a dividend at the moment.
Is CG Oncology stock halal?
Yes. CG Oncology passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
How has CG Oncology stock done over the past year?
Up 74.9% over the past twelve months, to $74.40. It traded between $37.37 and $80.68 and is 7.8% below its high.
Who are CG Oncology's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with CG Oncology's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.